IMR Press / EJGO / Volume 30 / Issue 6 / pii/2009150

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up

Show Less
1 Institute of Tumor Marker Oncology, Gouda (The Netherlands)
2 Department of Obstetrics and Gynaecology, Groene Hart Ziekenhuis, Gouda (The Netherlands)
3 Department of Obstetrics & Gyneacology, Ludwig-Maximilians-University, Munich (Germany)
4 Institute of Clinical Chemistry, University Hospital of Munich (Germany)
5 Department of Obstetrics and Gynecology, University Hospital Groningen (The Netherlands)
6 Department of Gynecology, University of Zürich (Switzerland)
7 Department of Gynecologic Oncology, University of Turin (Italy)
8 Mater Misericordiae University Hospital, Dublin (Ireland)
9 Department of Clinical Immunology, Medical University Wroclaw (Poland)
10 Privatklinik Döbling, Vienna International Health Center (Austria)
11 Department of Oncology, Medical School, Poznan (Poland)
12 Laboratory of Clinical Chemistry, Hospital Clinico Provincial, Barcelona (Spain)
13 Clinical Biochemistry, Royal Infirmary, Edinburgh (U.K.)
14 Department of Oncology, Western General Hospital, Edinburgh (U.K.)
15 Fujirebio Diagnostics AB, Gothenburg (Sweden)
16 IDL Biotech AB, Bromma (Sweden)
Eur. J. Gynaecol. Oncol. 2009, 30(6), 609–615;
Published: 10 December 2009

Purpose of investigation: To evaluate the prognostic significance for overall survival rate for the marker combination TPS and CA125 in ovarian cancer patients after three chemotherapy courses during long-term clinical follow-up. Methods: The overall survival of 212 (out of 213) ovarian cancer patients (FIGO Stages I-IV) was analyzed in a prospective multicenter study during a 10-year clinical follow-up by univariate and multivariate analysis. Results: In patients with ovarian cancer FIGO Stage I (34 patients) or FIGO Stage II (30 patients) disease, the univariate and multivariate analysis of the 10-year overall survival data showed that CA125 and TPS serum levels were not independent prognostic factors. In the FIGO Stage III group (112 patients), the 10-year overall survival was 15.2%; while in the FIGO Stage IV group (36 patients) a 10-year overall survival of 5.6% was seen. Here, the tumor markers CA125 and TPS levels were significant prognostic factors in both univariate and multivariate analysis (p < 0.0001). In a combined FIGO Stage III + FIGO Stage IV group (60 patients with optimal debulking surgery), multivariate analysis demonstrated that CA125 and TPS levels were independent prognostic factors. For patients in this combined FIGO Stage III + IV group having both markers below respective discrimination level, 35.3% survived for more than ten years, as opposed to patients having one marker above the discrimination level where the 10-year survival was reduced to 10% of the patients. For patients showing both markers above the respective discrimination level, none of the patients survived for the 10-year follow-up time. Conclusion: In FIGO III and IV ovarian cancer patients, only patients with CA 125 and TPS markers below the discrimination level after three chemotherapy courses indicated a favorable prognosis. Patients with an elevated level of CA 125 or TPS or both markers after three chemotherapy courses showed unfavorable prognosis. 

Ovarian cancer
CA 125
Back to top